Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer - Report - MDSpire

Emerging Immunotherapeutic Agents in Initial Clinical Trials for Head and Neck Malignancies

  • By

  • Harold Nathan Tan

  • Bettzy Stephen

  • Oriol Mirallas

  • Mohamed H. Derbala

  • Israa Salih

  • Lilibeth Castillo

  • Yali Yang

  • Hung Le

  • Lei Kang

  • Heather Lin

  • Joann Lim

  • Ecaterina E. Dumbrava

  • Timothy A. Yap

  • Jordi Rodón

  • Sarina A. Piha-Paul

  • Siqing Fu

  • Stéphane Champiat

  • Neal Akhave

  • Renata Ferrarotto

  • David S. Hong

  • Funda Meric-Bernstam

  • Faye Johnson

  • Aung Naing

  • July 16, 2026

Share

Clinical Report: Emerging Immunotherapeutic Agents in Initial Clinical Trials for Head and Neck Malignancies

Background

Head and neck squamous cell carcinoma (HNSCC) is a highly lethal cancer with complex biology and high recurrence rates. Despite advances in systemic therapy, survival rates have improved only marginally over the past three decades, emphasizing the need for new treatment strategies. Immune checkpoint inhibitors have changed the treatment landscape, but durable benefits remain limited, necessitating exploration of additional immunotherapeutic agents.

Data Highlights

No numerical data available in the source material.

Key Findings

  • Less than 20% of patients with HNSCC achieve long-term survival with current therapies.
  • Immune resistance in HNSCC is driven by both tumor-intrinsic and tumor-extrinsic mechanisms.
  • Emerging immune checkpoint inhibitors target pathways such as LAG-3, TIM-3, and TIGIT to combat immune exhaustion.
  • Agonists of costimulatory receptors like OX40 and 4-1BB aim to enhance T-cell function.
  • Cytokine-based therapies are being explored to stimulate cytotoxic T cells and natural killer cells.
  • Investigational agents are being evaluated for their safety and antitumor activity in early-phase trials.

Clinical Implications

The findings underscore the importance of developing new immunotherapeutic strategies to address the limitations of current treatments for HNSCC. Understanding the unique immunobiology of HNSCC is crucial for optimizing treatment responses and safety profiles.

Conclusion

As the field of immunotherapy for HNSCC evolves, further research is needed to define the clinical activity and safety of next-generation immune modulators. This will be essential for improving outcomes in patients with this challenging malignancy.

Related Resources & Content

  1. Nabil F. Saba, MD, The ASCO Post, 2017 -- New Horizons in Immunotherapy for Head and Neck Cancer
  2. Li et al, The ASCO Post, 2025 -- Neoadjuvant Combination Immunotherapy for Head and Neck Cancer
  3. Christine H. Chung, The ASCO Post, 2017 -- Targeted Therapy in the Age of Immunotherapy in Head and Neck Cancer
  4. Frontiers in Immunology — The biological characteristics of tertiary lymphoid structures in head and neck cancer
  5. NCCN Head and Neck Cancers Version 1.2026
  6. Addition of pembrolizumab to standard care improved event‐free survival for patients with HNSCC - Nierengarten - 2025 - Cancer - Wiley Online Library
  7. Surgical Outcomes in KEYNOTE-689: Neoadjuvant and Adjuvant Pembrolizumab (Pembro) in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) - International Journal of Radiation Oncology, Biology, Physics
  8. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial - PubMed
  9. Adding Nivolumab to Chemoradiotherapy After Surgery Can Decrease Chance of Recurrence in Patients With Head and Neck Cancer - ASCO
  10. Additional Immunotherapy to Standard of Care for Unresectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis - PubMed
  11. Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial - PubMed
  12. A phase 2 study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus cemiplimab plus placebo in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with positive PD-L1 expression. | Journal of Clinical Oncology
  13. Study Details | NCT04080804 | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | ClinicalTrials.gov
  14. First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC - PubMed
  15. Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy - PubMed
  16. BNT_2025 Q3 Exhibit99_1 (Quarterly Report)

Original Source(s)

Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer

  • by Harold Nathan Tan, Bettzy Stephen, Oriol Mirallas, Mohamed H. Derbala, Israa Salih, Lilibeth Castillo, Yali Yang, Hung Le, Lei Kang, Heather Lin, Joann Lim, Ecaterina E. Dumbrava, Timothy A. Yap, Jordi Rodón, Sarina A. Piha-Paul, Siqing Fu, Stéphane Champiat, Neal Akhave, Renata Ferrarotto, David S. Hong, Funda Meric-Bernstam, Faye Johnson, Aung Naing

  • July 16, 2026

Related Content

Social genomics and cancer – untangling nature from nurture in squamous cell carcinoma outcomes

Translation, cultural adaptation, and psychometric validation of the Arabic version of the university of Washington quality-of-life questionnaire in Jordanian head-and-neck cancer patients

Occult cervical microinvasive squamous cell carcinoma with superficial endometrial spread mimicking high-grade squamous intraepithelial lesion in a postmenopausal woman: a case report